Artelo Biosciences (ARTL) said Monday its first-in-human study of its non-opioid analgesic ART26.12 affirmed the "promising" safety and pharmacokinetic profile observed in preclinical trials.
Shares more than doubled as intraday trading volume catapulted to over 24.5 million from a daily average of about 73,000.
HC Wainwright upgraded Vor Biopharma (VOR) to a buy rating from neutral, with a price target of $3.
Shares surged 52%, with trading volume of over 52.9 million against a daily average of about 12.6 million.
Klotho Neurosciences (KLTO) said it is progressing with manufacturing and process development work for trials of KLTO-202, its gene therapy candidate for amyotrophic lateral sclerosis.
Shares advanced 61% as intraday trading volume soared to over 124.1 million from a daily average of about 39.2 million.
Price: 14.08, Change: +7.30, Percent Change: +107.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.